Bli medlem
Bli medlem

Du är här


Prothena Corporation plc: Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated

DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein
immunotherapies, today announced that clinical data from its Phase 1 single
ascending dose study of PRX003 in healthy volunteers will be highlighted in
an oral presentation at The European League Against Rheumatism Annual
European Congress of Rheumatology (EULAR 2016) to be held June 8-11 in

PRX003 is a monoclonal antibody targeting melanoma cell adhesion molecule
(MCAM), believed to be a critical mediator of Th17 cell pathogenesis, for the
potential treatment of inflammatory diseases where multiple cytokines play a
role. PRX003 is designed to address inflammation by targeting Th17 cells
upstream of the process that releases disease-causing cytokines into tissue.

The PRX003 Phase 1 clinical data will be highlighted in the following oral

Session #EULAR16-3570, Abstract #OP0205

Clinical and Preclinical Assessment of the Anti-MCAM Monoclonal Antibody
PRX003, a Potential Novel Treatment of Th17-mediated Inflammatory Diseases

* Presenter: Gene Kinney, PhD, Chief Scientific Officer and Head of Research
and Development, Prothena
* Session: Novel insights into B and T cell immunity in rheumatic disease
* Date and Time: Friday, June 10, 2016 11:20 a.m. BST
* Location: ExCeL London, Room S20

Prothena management plans to discuss the data during an audio webcast and
conference call on June 9, 2016 at 4:30 p.m. ET. Further details on how to
access the discussion will be provided on the day of the webcast.

About MCAM and Inflammatory Disease

Within the immune system, a small population of T cells known as Th17 cells,
initiate the body's response to infections, and are known to be a key
participant in both normal inflammatory reactions as well as pathogenic
autoimmune diseases. MCAM is a cell adhesion molecule expressed on the
surface of Th17 cells, and confers upon these cells the ability to interact
with vasculature and subsequently migrate from circulation into tissues, in
some cases to initiate or perpetuate a disease process. While only two to six
percent of T cells in circulation express MCAM, these cells secrete the Th17
signature cytokines, IL-17A and IL-17F, but can also produce other cytokines
such as such as IFN gamma, GM-CSF, TNF alpha and IL-22 that may play a role
in disease pathogenesis.

About PRX003

PRX003 is a monoclonal antibody being developed for the potential treatment of
inflammatory diseases where multiple cytokines play a role, including
psoriasis. PRX003 is designed to occupy and down-regulate MCAM, a cell
adhesion molecule expressed on the surface of Th17 cells, thereby
sequestering cells that secrete disease-causing cytokines in the bloodstream
and preventing their migration into tissues. As MCAM expressing T cells
appear to be disproportionately involved in propagation of inflammation,
targeting the T cell, rather than any individual cytokine, may provide a
highly specific way to impact multiple pathogenic processes, while leaving
the vast majority of immune cells unaffected. PRX003 may be useful for the
treatment of a variety of inflammatory diseases such as psoriasis, psoriatic
arthritis, rheumatoid arthritis, multiple sclerosis, sarcoidosis, uveitis,
giant cell arteritis, and Behcet's disease. For more information about
Prothena's ongoing Phase 1b clinical study of PRX003 in patients with
psoriasis please and search identifier

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology
company seeking to fundamentally change the course of progressive diseases
with its clinical pipeline of novel therapeutic antibodies. Fueled by its
deep scientific understanding built over decades of research in protein
misfolding and cell adhesion - the root causes of many serious or currently
untreatable amyloid and inflammatory diseases - Prothena has advanced several
drug candidates into clinical trials while pursuing discovery of additional
novel therapies. Our clinical pipeline of antibody-based product candidates
targets a number of potential indications including AL amyloidosis (NEOD001),
Parkinson's disease and other related synucleinopathies (PRX002) and
inflammatory diseases, including psoriasis (PRX003).

Forward-looking Statements

This press release contains forward-looking statements. These statements
relate to, among other things, PRX003's mechanism of action and potential use
as a treatment for variety of inflammatory diseases. These statements are
based on estimates, projections and assumptions that may prove not to be
accurate, and actual results could differ materially from those anticipated
due to known and unknown risks, uncertainties and other factors, including
but not limited to the risks, uncertainties and other factors described in
the "Risk Factors" sections of our Annual Report on Form 10-K filed with the
Securities and Exchange Commission (SEC) on February 25, 2016 and our
subsequent Quarterly Reports on Form 10-Q filed with the SEC. Prothena
undertakes no obligation to update publicly any forward-looking statements
contained in this press release as a result of new information, future events
or changes in Prothena's expectations.


Investors: Tran Nguyen, CFO

Media: Ellen Rose, Head of Communications


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation plc via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.